AG
UTHR icon

Advisor Group’s United Therapeutics UTHR Stock Holding History

Advisor Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$71K Sell
806
-176
-18% -$15.5K ﹤0.01% 3187
2019
Q3 		$78K Buy
982
+141
+17% +$11.4K ﹤0.01% 3079
2019
Q2 		$66K Sell
841
-32
-4% -$2.99K ﹤0.01% 3175
2019
Q1 		$103K Buy
873
+309
+55% +$36K ﹤0.01% 2833
2018
Q4 		$61K Sell
564
-74
-12% -$8.58K ﹤0.01% 3049
2018
Q3 		$81K Buy
638
+111
+21% +$13.7K ﹤0.01% 2913
2018
Q2 		$59K Sell
527
-114
-18% -$12.5K ﹤0.01% 2957
2018
Q1 		$72K Sell
641
-195
-23% -$24.8K ﹤0.01% 2799
2017
Q4 		$123K Buy
836
+87
+12% +$11.1K ﹤0.01% 2413
2017
Q3 		$88K Buy
749
+32
+4% +$4.09K ﹤0.01% 2512
2017
Q2 		$93K Buy
717
+12
+2% +$1.5K ﹤0.01% 2367
2017
Q1 		$96K Buy
705
+5
+0.7% +$757 ﹤0.01% 2183
2016
Q4 		$100K Sell
700
-30
-4% -$3.83K ﹤0.01% 2069
2016
Q3 		$87K Buy
730
+46
+7% +$5.53K ﹤0.01% 2104
2016
Q2 		$71K Buy
+684
New +$76.3K ﹤0.01% 2174

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Advisor Group's UTHR Position: Q4 2019 in Review

Advisor Group reduced its United Therapeutics (UTHR) stake by 18% in Q4 2019, selling an estimated $15.5K and leaving 806 shares worth $71K. The position accounts for ﹤0.01% of the portfolio, ranked #3187.

Advisor Group first reported a position in UTHR in Q2 2016 and has held it in 15 quarters since. The position peaked at $123K in Q4 2017. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

  • Advisor Group held 806 shares of United Therapeutics worth $71K as of Q4 2019.
  • Advisor Group sold 176 United Therapeutics shares in Q4 2019, an estimated $15.5K.
  • United Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3187 holding.
  • Advisor Group first reported a position in United Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's United Therapeutics position peaked at $123K in Q4 2017.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.